Literature DB >> 7441496

Disposition of enflurane in obese patients.

M S Miller, A J Gandolfi, R W Vaughan, J B Bentley.   

Abstract

The disposition of enflurane, a volatile halogenated anesthetic, was studied in obese (n = 26) and nonobese (n = 8) consenting adult subjects undergoing elective intra-abdominal surgical procedures. Enflurane and fluoride ion, a nephrotoxic metabolite of enflurane, were measured in the blood of subjects before, during and up to 24 hr after exposure to pharmacologically equivalent doses of enflurane [approximately 2.0 MAC hr (the minimal alveolar concentration at which 50% of humans do not respond to a painful stimulus)] Arterial enflurane in obese subjects reached maximal concentrations 3 times faster than nonobese subjects who reached similar blood levels 80 min after the initiation of anesthesia. The blood/gas partition coefficient for enflurane in the obese was found to be 30% lower than that in the nonobese (0.99 +/- 0.02 vs. 1.42 +/- 0.02) and may possibly explain the observed differences in enflurane uptake. The rate at which inorganic fluoride appeared in obese serum (5.5 microM/hr) was twice that seen in the nonobese group. No differences in urinary fluoride excretion were demonstrated. Maximum serum fluoride concentration occurred 2 hr postenflurane anesthesia in both groups with the obese having a 60% higher concentration (27.8 +/- 2.0 vs. 17.0 +/- 3.0 microM), indicating increased biotransformation in the obese. Hepatic triglyceride content was demonstrated to be unrelated to the increased enflurane biotransformation observed in obese subjects. Equations are presented for the estimation of mean maximum serum inorganic fluoride levels in both obese and nonobese subjects after enflurane anesthesia.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7441496

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Carpal spasm observed during and after sevoflurane anesthesia.

Authors:  S Watanabe; H Ashimura; S Inomata; M Taguchi; K Shibata
Journal:  J Anesth       Date:  1995-03       Impact factor: 2.078

Review 2.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

3.  Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.

Authors:  Cyrus Ghobadi; Trevor N Johnson; Mohsen Aarabi; Lisa M Almond; Aurel Constant Allabi; Karen Rowland-Yeo; Masoud Jamei; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2011-12-01       Impact factor: 6.447

4.  The Influence of Obesity on the Pharmacokinetics of Dioxin in Mice: An Assessment Using Classical and PBPK Modeling.

Authors:  Claude Emond; Michael J DeVito; Janet J Diliberto; Linda S Birnbaum
Journal:  Toxicol Sci       Date:  2018-07-01       Impact factor: 4.849

Review 5.  Clinical pharmacokinetics of drugs in obesity. An update.

Authors:  G Cheymol
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

6.  Fluorinated anaesthetic nephrotoxicity: an update.

Authors:  R I Mazze
Journal:  Can Anaesth Soc J       Date:  1984-05

7.  Plasma fluoride concentration and urinary fluoride excretion in obese and non-obese patients following enflurane anesthesia.

Authors:  Y Tohyama
Journal:  J Anesth       Date:  1987-09-01       Impact factor: 2.078

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.